Tuesday 23 July 2019 ,
Tuesday 23 July 2019 ,
Latest News
  • DENGUE DANGER: 400 hospitalised a day in capital
  • LPG cylinders getting sold as scrap, creates problem for industry
  • Step up campaign against lynching: Police HQ asks SPs
  • Flood situation improving; 8 Tangail upazilas in danger
  • 1,100 primary schools shut due to flood
13 May, 2019 00:00 00 AM

FDA approves Eticovo (etanercept-ykro), a Biosimilar to Enbrel

drugs.com
FDA approves Eticovo (etanercept-ykro), a Biosimilar to Enbrel

Samsung Bioepis Co., Ltd. recently announced that the US Food and Drug Administration (FDA) has approved Eticovo (etanercept-ykro), a biosimilar referencing Enbrel (etanercept), across all eligible indications for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis and polyarticular juvenile idiopathic arthritis. Eticovo is Samsung Bioepis’ second anti-TNF biosimilar approved for marketing in the United States (US).

“The approval of Eticovo adds to our growing portfolio of anti-TNF medicines in the US, where we believe biosimilars can bring meaningful value to the country’s healthcare system,” said Christopher Hansung Ko, President & CEO of Samsung Bioepis. “Through relentless process innovation and an uncompromising commitment to quality, we remain dedicated to advancing one of the industry's strongest biosimilar pipelines."

In a 52-week Phase III clinical study, which randomized 596 patients with rheumatoid arthritis across 70 sites in 10 countries, Eticovo demonstrated comparable safety and efficacy to the etanercept reference product (Enbrel®), as evidenced in ACR20 response rate of 80.8% in the Eticovo arm versus 81.5% in the Enbrel® arm ii. This confirmed the 24-week study results of 78.1% in the Eticovo arm versus 80.3% in the Enbrel® arm iii.

About Eticovo (etanercept-ykro)

Eticovo is a tumor necrosis factor (TNF) blocker approved in the US for the following indications:

Rheumatoid Arthritis - Eticovo is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Eticovo can be initiated in combination with methotrexate (MTX) or used alone.

Polyarticular Juvenile Idiopathic Arthritis - Eticovo is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older.

Psoriatic Arthritis - Eticovo is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Eticovo can be used with or without methotrexate.

Ankylosing Spondylitis - Eticovo is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS).

Plaque Psoriasis - Eticovo is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

Warning: Serious Infections and Malignancies

Serious Infections

Patients treated with etanercept products are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) and Adverse Reactions (6)]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Eticovo should be discontinued if a patient develops a serious infection or sepsis.

Reported infections include:

Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before Eticovo use and during therapy. Treatment for latent infection should be initiated prior to Eticovo use.

Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.

Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with Eticovo should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Eticovo, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

Malignancies

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including etanercept products.

These are not all of the risks associated with Eticovo. The Eticovo Prescribing Information carries warnings regarding serious infections, neurologic reactions, malignancies, patients with heart failure, hematologic reactions, Hepatitis B reactivation, allergic reactions, immunizations, autoimmunity, immunosuppression, use in Wegener’s Granulomatosis patients, use with Anakinra or Abatacept and use in patients with moderate to severe alcoholic hepatitis.

Comments

Most Viewed
Digital Edition
More story
Editor Speaks

Editor Speaks

Dengue is creating a have in Bangladesh. This year in the capital till now 4549 people admitted in the hospital suffering from this disease. Recently…
Dengue --- a bird's eye view

Dengue --- a bird's eye view

Introduction Dengue (pronounced as Dengee) is a Spanish word. It probably originated fro the word Dinga in the Swahili phrase Ka-dinga pepo means disease…
Dengue and severe dengue

Dengue and severe dengue

Key facts • Dengue is a mosquito-borne viral infection. •    The infection causes flu-like illness, and occasionally develops…
Dengue

Dengue

How Dengue shock occur? Macrophage and monocyte infection by the Dengue virus sets off a chain of reactions causing release of cytokines and vaso active…
Children over six may be at greater risk of dengue infection

Children over six may be at greater risk of dengue infection

A new study with icddr,b identifies various household and community level risk factors that increase the risk of Dengue fever virus (DENV) infection.…
Phototherapy for psoriasis

Phototherapy for psoriasis

RUTH JESSEN HICKMAN, MD Phototherapy, also known as UV light therapy, is one of the most effective treatments for psoriasis. It involves exposing the…
3 Habits that can sabotage your metabolism

3 Habits that can sabotage your metabolism

When we’re having trouble losing weight, it can be tempting to place the blame entirely on our metabolism. Yes, metabolism matters, but it’s…
Researchers tie metabolic enzyme to obesity and fatty liver disease

Researchers tie metabolic enzyme to obesity and fatty liver disease

CHRIS WORTHY Researchers from Clemson University's Environmental Toxicology Program have published research connecting an enzyme associated with detoxification…
Are sugary drinks causing cancer?

Are sugary drinks causing cancer?

JAMES GALLAGHER  Sugary drinks - including fruit juice and fizzy pop - may increase the risk of cancer, French scientists say. The link was suggested…
icddr,b extends its laboratories service operation to 24 hours a day

icddr,b extends its laboratories service operation to 24 hours a day

Starting from 15 July 2019, icddr,b’s globally recognised diagnostic centre at Mohakhali, Dhaka is now operating its services 24 hours a day, 7…
Climate change cause health risk for children

Climate change cause health risk for children

Negative effects of climate change have resulted in health risk of our children. The government should take necessary steps for saving the future generation,…
DR Congo Ebola outbreak declared global health emergency

DR Congo Ebola outbreak declared global health emergency

The World Health Organization has declared the Ebola crisis in the Democratic Republic of Congo a "public health emergency of international concern".…
Safety practice violations ID'd in septic arthritis outbreak

Safety practice violations ID'd in septic arthritis outbreak

Breaches of recommended infection prevention practices have been identified in an outbreak of septic arthritis cases after intra-articular injections…
FDA approves Xembify (immune globulin subcutaneous) for primary immunodeficiencies

FDA approves Xembify (immune globulin subcutaneous) for primary immunodeficiencies

Grifols, a leading global producer of plasma-derived medicines, announced recently that Xembify, its new 20% subcutaneous immunoglobulin, has been approved…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting